Edap Tms (FOCL) Gross Margin (2009 - 2026)
Edap Tms' (FOCL) quarterly Gross Margin came in at 45.73% in Q1 2026, up 373.0% YoY from 9.67% in Q1 2025, and up 7.42% on a QoQ basis from 42.57% in Q4 2025.
Edap Tms (FOCL) Gross Margin (2009 - 2026) Analysis & Trends
Edap Tms (FOCL) has 18 years of Gross Margin data on file, last reported at 45.73% in Q1 2026.
- Quarterly Gross Margin rose 373.0% year-over-year to 45.73% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 43.42% (up 224.0% YoY) and the FY2025 annual result came in at 42.54%, up 112.0% from the prior year.
- Gross Margin advanced to 45.73% in Q1 2026, from 42.57% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 45.92% in Q4 2022 to a low of 35.46% in Q3 2023.
- A 5-year average of 42.05% and a median of 42.57% in 2025 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2023 — Gross Margin slumped 552 bps — and 2025, when it surged 504 bps.
- Tracing FOCL's Gross Margin over 5 years: stood at 45.92% in 2022, then declined by 5 bps to 43.65% in 2023, then rose by 3 bps to 44.78% in 2024, then dropped by 5 bps to 42.57% in 2025, then grew by 7 bps to 45.73% in 2026.
- The last three Gross Margin figures came in at 45.73% (Q1 2026), 42.57% (Q4 2025), and 43.02% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Mckesson | 102.37 Bn | 97.20 Bn | 3.69 Bn | 3.50% |
| 2 | Cencora | 61.59 Bn | 58.78 Bn | 3.61 Bn | 4.26% |
| 3 | Cardinal Health | 53.90 Bn | 49.05 Bn | 2.56 Bn | 4.02% |
| 4 | Henry Schein | 10.03 Bn | 9.88 Bn | 1.10 Bn | 31.84% |
| 5 | Akso Health | 715.48 Mn | 715.28 Mn | - | - |
| 6 | Edap Tms | 156.12 Mn | 134.57 Mn | 7.34 Mn | 55.58% |
| 7 | Accendra Health | 95.49 Mn | 87.83 Mn | 263.41 Mn | 42.95% |
| 8 | 111 | 30.87 Mn | 109.39 Mn | 18.18 Mn | 5.31% |
| 9 | Cosmos Health | 13.20 Mn | 10.75 Mn | 1.51 Mn | 7.96% |
| 10 | VitaNova Life Sciences | 11.51 Mn | 9.91 Mn | 264,662.00 | 14.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 45.73% |
| Dec 31, 2025 | 42.57% |
| Sep 30, 2025 | 43.02% |
| Jun 30, 2025 | 42.53% |
| Mar 31, 2025 | 42.01% |
| Dec 31, 2024 | 44.78% |
| Sep 30, 2024 | 39.36% |
| Jun 30, 2024 | 37.48% |
| Mar 31, 2024 | 42.83% |
| Dec 31, 2023 | 43.65% |
| Sep 30, 2023 | 35.46% |
| Jun 30, 2023 | 39.61% |
| Mar 31, 2023 | 40.77% |
| Dec 31, 2022 | 45.92% |
| Sep 30, 2022 | 40.99% |
| Jun 30, 2022 | 43.80% |
| Mar 31, 2022 | 44.29% |
| Dec 31, 2021 | 44.45% |
| Sep 30, 2021 | 38.40% |
| Jun 30, 2021 | 40.73% |